NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug aims to restore sight in macular degeneration patients
Disease control Not yet recruitingThis study is testing a drug called faricimab for people with wet age-related macular degeneration (nAMD), a condition that causes vision loss. Researchers will give 50 patients four initial eye injections, then more as needed, to see if it improves vision and eye structure. The …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New eye injection shows promise for blinding disease
Disease control Not yet recruitingThis early-stage study tests a new drug called GB10, given as an eye injection, for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 48 participants will receive either a single or multiple doses to check safety and how well it works.…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE1 • Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New eye drug aims to match leading treatment for blinding disease
Disease control Not yet recruitingThis study tests a new eye injection called QL1207H against an approved drug (Eylea) for people with wet age-related macular degeneration, a leading cause of vision loss. About 356 adults aged 50 and older with active disease will receive injections every 4 weeks for 3 doses, the…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Wet AMD patients needed for Long-Term safety check of eye implant
Disease control Not yet recruitingThis study looks at the long-term safety of an eye implant called OTX-TKI for people with wet age-related macular degeneration (nAMD). About 850 participants who already finished a 2-year study on this implant will be followed for up to 144 weeks. The main goal is to track any si…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Could a cotton swab replace the metal speculum for eye injections?
Symptom relief Not yet recruitingThis study tests if using a cotton-tipped applicator to hold the eyelid open during eye injections causes less pain and is faster than the standard metal speculum. About 120 people with certain eye conditions will take part. The goal is to see which method patients prefer and if …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: NA • Sponsor: Jakkrit Juhong • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC